早期无引导人脑类器官神经血管生态位建模到允许的雏鸡胚绒毛膜尿囊膜中
February 16th, 2024
在这里，我们提出了一种将处于多个成熟阶段的人脑类器官移植到鸡绒毛膜尿囊膜 （CAM） 中的方案。大脑类器官是按照无指导的标准化协议生长的。
我旨在解决的关键问题围绕着正常发育背景下涉及人脑形成的机制和过程，以及各种病理状态。这包括调查影响大脑发育的因素，例如遗传学、环境和表观遗传影响。获得与成人大脑非常相似的大脑类器官，包括血管形成、血脑屏障功能、小胶质细胞的存在和细胞多样性是具有挑战性的。
克服这一点对于开发更具生理相关性的大脑类器官模型至关重要，这些模型可以有效地模仿成人大脑以增强临床应用。通过我们的研究，我们为将人脑类器官移植到绒毛膜尿囊膜中提供了最佳条件，以确保小胶质细胞的良好发育。这种临床改进对于该领域即将为大脑类器官生成合成血管化环境的努力至关重要。
与其他技术相比，我们的协议的优势在于其高效率和成本效益。我们在使用农场鸡的受精卵移植可行的类器官方面取得了很高的成功率。未来，我们的实验室将专注于对与类器官相关的新脉管系统进行功能评估，探索这种血管设计模型在静脉纳米医学应用中的潜在用途。
此外，我们的目标是评估这些纳米药物在人类中枢神经系统中的生物分布。
概述
本研究提出了一种将人脑类器官在不同成熟阶段嫁接到鸡胚绒膜尿囊膜（CAM）的协议。研究重点是提高脑类器官模型的生理相关性以用于临床应用。
关键研究组成部分
科学领域
- 神经科学
- 发育生物学
- 病理学
背景
- 人脑类器官对于研究大脑发育至关重要。
- 挑战包括实现与成年人类大脑相似的血管化和功能性。
- 小胶质细胞的存在和细胞多样性对于现实模型至关重要。
- 将类器官移植到CAM可以改善其发育。
研究目的
- 调查人类大脑形成的机制。
- 优化移植脑类器官的条件。
- 增强类器官模型中小胶质细胞的发育。
使用的方法
- 将人脑类器官嫁接到鸡胚绒膜尿囊膜。
- 利用未指导的标准化协议进行类器官生长。
- 评估小胶质细胞和血管化的发育。
- 评估血脑屏障的功能性。
主要结果
- 成功在多个成熟阶段嫁接脑类器官。
- 观察到小胶质细胞发育条件得到改善。
- 增强了类器官模型对临床应用的生理相关性。
- 对于脑类器官的合成血管化环境提供了见解。
结论
- 该研究为脑类器官移植提供了一个有价值的协议。
- 研究结果有助于理解大脑发育机制。
- 未来的研究可以在这些结果基础上改进类器官模型。
常见问题
Executive Industry Relevance
Modeling the neurovascular niche using human brain organoids engrafted into the chick chorioallantoic membrane (CAM) addresses a critical gap in recapitulating human brain development and vascularization in preclinical systems. This approach enables the study of cellular maturation, cytoarchitectural changes, and microglial development in a cost-effective, scalable, and physiologically relevant context. The method supports early-stage target validation and mechanistic de-risking for neurodevelopmental and neurovascular research portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of neurodevelopmental pathways and cellular interactions in a human-relevant context.
- Supports mechanistic de-risking by modeling the influence of vascularized environments on organoid maturation.
- Facilitates functional target validation by observing stage-dependent cytoarchitectural changes.
Screening & Assay Development
- Provides a standardized, reproducible platform for evaluating organoid viability and cellular composition post-engraftment.
- Enables quantitative assessment of glial and neuronal markers across maturation stages.
- Supports assay readiness for compound screening in vascularized organoid systems.
Translational & Preclinical Research
- Aligns with disease-relevant modeling by capturing human brain developmental milestones in vivo-like conditions.
- Facilitates translational biomarker discovery through histological and cellular analyses.
- Supports risk-adjusted advancement of neurovascular targets by providing predictive data on organoid integration and maturation.
Pipeline & Workflow Integration
This engraftment protocol bridges early discovery and preclinical validation by enabling hypothesis testing in a vascularized, immunologically permissive system.
- Discovery Biology: Supports mechanistic studies of neurovascular interactions and cellular maturation.
- Screening: Delivers reproducible, quantitative outputs for cellular composition and cytoarchitecture.
- Analytics: Provides histological and immunohistochemical readouts for comparative analysis across conditions.
- Translational Research: Offers continuity from in vitro organoid development to in vivo-like modeling for biomarker alignment.
- Enterprise Reuse: Establishes a scalable, cost-effective platform adaptable to diverse neurodevelopmental research needs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in neurodevelopmental modeling and target validation.
- Operational Value: Enhances standardization, reproducibility, and scalability of organoid engraftment workflows.
- Strategic Value: Improves go/no-go decision-making by providing robust, physiologically relevant data early in the pipeline.
- Portfolio Impact: Enables risk-adjusted prioritization of neurovascular and neurodevelopmental programs.
Implementation Considerations
- Requires expertise in organoid culture, embryology, and histological analysis.
- Needs access to sterile instrumentation, incubators, and imaging infrastructure.
- Demands cross-team standardization for reproducible engraftment and analysis.
- Adaptable to various organoid maturation stages and potentially other tissue types.
- Limited by absence of neovascularization within organoids, as observed in current outputs.
